The Division of Molecular Pathology is directed by Dr. Thomas W. Prior and has established itself as one of the major academic DNA testing centers for genetic diseases and inherited cancer syndromes. The lab is also involved in identifying new types of mutations, developing genotype phenotype associations and advancing molecular technologies.
The Division is also involved in several research projects and clinical trials including: an international Phase III trial of if the FLT3 inhibitor, midostaurin, added to standard chemotherapy for AML (funded by Novartis Pharmaceutical Corporation), Project Cure: SMN2 Copy Number Assay (funded by the Families of SMA) and Population Carrier Screening of Spinal Muscular Atrophy (funded by the Claire Altman Hein Foundation).
Dr. Prior currently serves on the Board of Directors of the American Board of Medical Genetics, National Task Force for Genetic Screening, Families of Spinal Muscular Atrophy Research Committee, American College of Medical Genetics Education Committee.